| Overview |
| bs-17096R-Cy5.5 |
| KAT5 (Ser86) Polyclonal Antibody, Cy5.5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse, Rat |
| Human, Dog, Cow, Sheep, Pig, Horse, Rabbit |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated synthesised phosphopeptide derived from human KAT5 around the phosphorylation site of Ser86 |
| Ser86 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 10524 |
| Q92993 |
| Cytoplasm, Nucleus |
| Histone acetyltransferase KAT5; KAT5; 60 kDa Tat-interactive protein; Tip60; Histone acetyltransferase HTATIP; HIV-1 Tat interactive protein; Lysine acetyltransferase 5; cPLA(2)-interacting protein; KAT5; HTATIP; TIP60 |
| Catalytic subunit of the NuA4 histone acetyltransferase complex which is involved in transcriptional activation of select genes principally by acetylation of nucleosomal histones H4 and H2A. This modification may both alter nucleosome-DNA interactions and promote interaction of the modified histones with other proteins which positively regulate transcription. This complex may be required for the activation of transcriptional programs associated with oncogene and proto-oncogene mediated growth induction, tumor suppressor mediated growth arrest and replicative senescence, apoptosis, and DNA repair. NuA4 may also play a direct role in DNA repair when recruited to sites of DNA damage. Directly acetylates and activates ATM. In case of HIV-1 infection, interaction with the viral Tat protein leads to KAT5 polyubiquitination and targets it to degradation. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz